{
  "id": 11015582,
  "title": "Why is Rafael stock crashing today?",
  "url": "https://urgent.news/2026/09/30/why-is-rafael-stock-crashing-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T19:32:46.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-rafael-stock-crashing-today-93CH-4925770"
  },
  "original_language": "en",
  "account": "Rafael Holdings Inc stock experienced a dramatic -36.0% decline in afternoon trading following Cyclo Therapeutics' announcement that its Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C failed to meet statistical significance on its primary endpoint. The disappointing results, disclosed in a press release and investor conference call, saw shares drop sharply at the opening bell. While a prespecified analysis of patients on background miglustat and/or leucine therapy showed statistical significance, reflecting a 71% reduction in disease progression compared to placebo, the overall primary endpoint miss left investors disappointed. Rafael had planned to submit a New Drug Application to the FDA in Q4 2026; however, the partial efficacy results did not meet the expectations of investors who were anticipating a clean primary endpoint win. Trading volume surged to over 12 times the stock's 100-day average, leaving the stock trading as low as $1.20 intraday, well below its 52-week high of $3.96. The company maintains that it remains on track for an FDA submission, but the partial nature of the trial results proved disheartening for those relying on this de-risking event. With no broader market stress to offset the company-specific decline, Rafael's stock suffered one of its steepest single-session drops, unaffected by broader market gains in U.S. equity indices.",
  "summary": null,
  "key_points": [
    "Rafael stock drops 36% after Phase 3 study fails primary endpoint",
    "Cyclo Therapeutics' Niemann-Pick Disease Type C trial results negative",
    "Rafael planned FDA submission for Q4 2026, now facing investor disappointment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}